[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100257649":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":19,"centralContacts":23,"locations":32,"responsibleParty":83,"collaborators":7,"id":85,"slug":86,"hasResults":87,"nctId":88,"briefTitle":89,"officialTitle":89,"acronym":7,"eligibilityCriteria":90,"healthyVolunteers":87,"sex":91,"minAge":92,"maxAge":7,"enrollmentInfo":7,"targetDuration":7,"studyType":93,"phases":7,"briefSummary":94,"conditions":95,"keywords":7,"overallStatus":35,"whyStopped":7,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Eli Lilly and Company","INDUSTRY",null,[9,13,15,17],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DRUG","LY2503029","Administered orally.",{"type":10,"name":14,"description":12,"armGroupLabels":7,"otherNames":7},"LY3023414",{"type":10,"name":16,"description":12,"armGroupLabels":7,"otherNames":7},"LY3838915",{"type":10,"name":18,"description":12,"armGroupLabels":7,"otherNames":7},"LY3847429",[20],{"name":21,"affiliation":5,"role":22},"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC\u002FGMT - 5 hours, EST)","STUDY_DIRECTOR",[24,29],{"name":25,"role":26,"phone":27,"phoneExt":7,"email":28},"Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or","CONTACT","1-317-615-4559","LillyTrials@Lilly.com",{"name":30,"role":26,"phone":7,"phoneExt":7,"email":31},"Physicians interested in becoming principal investigators please contact","clinical_inquiry_hub@lilly.com",[33,53,68],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"UCLA Medical Center","AVAILABLE","Torrance","California","90505","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-118.34063,33.83585,{"lat":45,"lon":44},[48,50],{"name":7,"role":26,"phone":49,"phoneExt":7,"email":7},"310-325-8252",{"name":51,"role":52,"phone":7,"phoneExt":7,"email":7},"Dr. Parvin Fatheddin Peddi","PRINCIPAL_INVESTIGATOR",{"facility":54,"status":35,"city":55,"state":56,"zip":57,"country":39,"countryCode":40,"cosmosGeoPoint":58,"geoPoint":62,"contacts":63},"Fort Wayne Oncology & Hematology","Fort Wayne","Indiana","46804",{"type":42,"coordinates":59},[60,61],-85.12886,41.1306,{"lat":61,"lon":60},[64,66],{"name":7,"role":26,"phone":65,"phoneExt":7,"email":7},"260-436-0800",{"name":67,"role":52,"phone":7,"phoneExt":7,"email":7},"Dr. Sunil Babu",{"facility":69,"status":35,"city":70,"state":71,"zip":72,"country":39,"countryCode":40,"cosmosGeoPoint":73,"geoPoint":77,"contacts":78},"Sarah Cannon Cancer Center","Nashville","Tennessee","37203",{"type":42,"coordinates":74},[75,76],-86.78444,36.16589,{"lat":76,"lon":75},[79,81],{"name":7,"role":26,"phone":80,"phoneExt":7,"email":7},"615-329-7274",{"name":82,"role":52,"phone":7,"phoneExt":7,"email":7},"Dr. Howard A. Burris III",{"type":84,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100257649","master-rollover-protocol-for-continued-safety-assessment-of-study-drug-100257649",false,"NCT02632994","Master Rollover Protocol for Continued Safety Assessment of Study Drug","Inclusion Criteria:\n\n* To be eligible patients must be currently receiving benefit in a concluded Lilly study for a compound that has opened an addendum in the continued access protocol.\n\nExclusion Criteria:\n\n* Patients must not be concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.","ALL","18 Years","EXPANDED_ACCESS","This study is for patients who have participated in a previous study and who continue to receive benefit to have continued access to study drug and\u002For treatment.",[96],"Cancer","2026-06-22",{"date":99,"type":100},"2026-06-25","ACTUAL",{"name":5,"class":6},3]